SanBio Company Limited (TYO:4592)

Market Cap	70.25B -66.6%
Revenue (ttm)	n/a
Net Income	-3.64B
EPS	-47.70
Shares Out	78.06M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	865,800
Open	902.00
Previous Close	924.00
Day's Range	886.00 - 912.00
52-Week Range	858.00 - 2,933.00
Beta	0.29
Analysts	Hold
Price Target	1,400.00 (+55.56%)
Earnings Date	Dec 15, 2026

About SanBio Company

SanBio Company Limited engages in the development, production, and sale of regenerative cell medicines for the central nervous system in Japan and the United States. It develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury. The company’s research pipeline products also comprise SB623 for chronic disease, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, Alzheimer's disease, etc.; SB618 to treat peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 33
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4592

Analyst Summary

According to 5 analysts, the average rating for 4592 stock is "Hold." The 12-month stock price target is ¥1,400, which is an increase of 55.56% from the latest price.

Price Target

¥1,400

(55.56% upside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 26, 2026

Data Sources Report a data error